Stage 4 Cancer in America 2026
A stage 4 cancer diagnosis is the moment a disease stops being confined to one part of the body and becomes something the whole body has to fight. For patients and families, the word “stage 4” carries a weight that no other medical term quite matches, and it often arrives with more questions than answers about what comes next.
Across the United States, the numbers behind this stage of disease have shifted more in the past decade than in the several before it. Survival outcomes that once felt fixed have moved substantially for some cancer types, while others remain largely unchanged, and the reasons behind that divide say as much about how cancer is caught as they do about how it is treated.
Quick Facts: Stage 4 Cancer in the US, 2026
| Metric | Figure |
|---|---|
| New cancer cases expected in 2026 | 2,114,850 (~5,800 per day) |
| Total cancer deaths expected in 2026 | 626,140 |
| 5-year survival, all cancers combined (all stages) | 70% |
| 5-year survival, distant/stage 4 disease (all cancers combined) | 35% |
| Distant-stage survival in the mid-1990s | 17% |
| Women currently living with stage 4 metastatic breast cancer | ~168,000 |
| Average annual cancer care cost, last year of life | ~$121,700 |
| Average annual cancer care cost, continuing/maintenance phase | ~$7,100 |
Source: American Cancer Society, Cancer Statistics 2026; National Cancer Institute SEER Program
How Many Cancers Are Caught at Stage 4
Stage 4, also called distant-stage or metastatic disease, means the cancer has spread beyond its original organ to reach distant lymph nodes, organs, or bone. How often this happens at initial diagnosis varies enormously by cancer type, largely driven by whether a reliable screening test exists.
Share of Diagnoses Made at Distant (Stage 4) Stage, US
| Cancer Type | Share Diagnosed at Distant Stage |
|---|---|
| Lung (non-small cell) | 54.2% |
| Colorectal | 23.3% |
| Breast | 7.2% |
| Prostate | 3.0% |
Source: JAMA Network Open, federal cancer-registry cohort analysis, 2026
Share of Diagnoses Made at Distant Stage — US, 2026
Lung (NSCLC) ██████████████████████████████████████████████████ 54%
Colorectal ███████████████████████ 23%
Breast ███████ 7%
Prostate ███ 3%
Lung cancer sits at the top of this list for a straightforward reason: there is no routine population-wide screening test most smokers or former smokers actually receive, and early symptoms are easy to mistake for a lingering cough or seasonal illness. By the time imaging is ordered, more than half of non-small cell lung cancer cases have already spread to distant sites, and roughly three in four are found at regional or distant stage combined.
Prostate and breast cancer sit at the opposite end for the opposite reason. Routine PSA testing and mammography screening catch the overwhelming majority of cases while they are still localized, which is a major part of why the overall survival outlook for these two cancers looks so different from lung cancer’s, despite prostate cancer being the single most commonly diagnosed cancer in American men.
Where Stage 4 Cancer Spreads: Common Metastasis Sites by Type
Stage 4 is often described as a single category, but where a cancer spreads to matters almost as much as the fact that it has spread at all, since different distant sites carry very different symptom burdens and treatment options.
Most Common Metastasis Sites by Primary Cancer Type
| Primary Cancer | Most Common Distant Sites |
|---|---|
| Prostate | Bone (89%), liver (10%) |
| Breast | Bone (51%), liver/soft tissue (19%), pleura (16%), lung (14%), brain (4%) |
| Lung | Bone (39%), brain (30%), liver (24%) |
| All cancers combined | Bone (42%), liver (35%), lung (21%) |
Source: Clinical Landscape of Cancer Metastases, population registry study of 1.25 million patients, 1987–2012, updated analysis
Bone is the single most common destination for metastatic cancer across nearly every major cancer type, which explains why bone pain, fractures, and elevated calcium levels are such frequent complications of stage 4 disease regardless of where the cancer originated. Prostate cancer stands out even within this pattern: 89% of men with metastatic prostate cancer have bone involvement, a rate high enough that oncologists frequently order a bone scan as a near-default part of staging once distant disease is suspected.
Breast cancer’s spread pattern looks different depending on tumor subtype, which is part of why oncologists increasingly treat “stage 4 breast cancer” as a group of related but distinct diseases rather than one condition. Lung cancer’s tendency to spread to the brain in roughly 30% of cases also explains why neurological symptoms, headaches, seizures, or sudden changes in coordination or speech are sometimes the first sign that leads to a lung cancer diagnosis in the first place, well before any respiratory symptom prompts a doctor’s visit.
Stage 4 Survival Rates by Cancer Type
Once a cancer has reached stage 4, the outlook depends heavily on which organ it started in. Some cancer types have seen survival numbers move dramatically over the past three decades; others have barely budged.
5-Year Relative Survival Rate — Distant-Stage (Stage 4) Cancer, US 2026
| Cancer Type | 5-Year Survival, Distant Stage |
|---|---|
| Prostate | 37% |
| Melanoma | 35% |
| Breast | 32% |
| Myeloma | 62%* |
| Liver | 22% |
| Rectal | 18% |
| Colorectal (overall) | 13–17% |
| Lung, non-small cell | 9–12% |
| Stomach | 8% |
| Lung, small cell | 3% |
| Pancreatic | 2–3.4% |
*Myeloma is staged differently from solid tumors, so this figure reflects overall survival rather than a distant-stage-only measure. Source: NCI SEER Program, 2015–2021 diagnosis cohort; CA: A Cancer Journal for Clinicians, Cancer Statistics 2026
5-Year Survival Rate — Distant-Stage Cancer, 2026
Prostate █████████████████████████████████████ 37%
Melanoma ███████████████████████████████████ 35%
Breast ████████████████████████████████ 32%
Liver ██████████████████████ 22%
Rectal ██████████████████ 18%
Colorectal █████████████ 13%
Lung (NSCLC) █████████ 9%
Pancreatic ███ 3%
The gap between pancreatic cancer’s 2–3.4% and prostate cancer’s 37% is one of the starkest contrasts in all of oncology, and it comes down to a mix of biology and timing. Pancreatic tumors tend to grow silently, sit deep in the abdomen where symptoms surface late, and resist most standard chemotherapy regimens once they’ve spread, which is why the disease continues to rank among the deadliest despite decades of research funding directed at it.
Melanoma tells a very different story and is arguably the biggest survival success of the past fifteen years. A diagnosis that carried under a 10% five-year survival rate before 2011 now sits at 35%, and some clinical follow-up data suggests roughly half of patients who respond to combination immunotherapy are still alive and cancer-free a full decade later — a timeline that simply didn’t exist for stage 4 melanoma patients a generation ago.
Cancer Deaths in 2026: Where Stage 4 Disease Does the Most Damage
Stage 4 disease is responsible for the overwhelming majority of the 626,140 cancer deaths expected in the US in 2026, even though it accounts for a much smaller share of total diagnoses across most cancer types.
Estimated US Cancer Deaths by Type, 2026
| Cancer Type | Estimated Deaths, 2026 |
|---|---|
| Lung and bronchus | 124,990 |
| Breast (female) | 42,140 |
| Prostate | 36,320 |
| Colorectal and pancreatic combined | Second- and third-leading causes, ranked below lung |
Source: American Cancer Society, Cancer Facts & Figures 2026
Lung cancer alone is projected to kill nearly 125,000 Americans in 2026, more than colorectal and pancreatic cancer combined, despite ranking third in new diagnoses behind prostate and breast cancer. That single fact captures the core problem with stage 4 disease: mortality tracks much more closely with how early a cancer is typically caught than with how common it is. About 40% of newly diagnosed cancers in US adults are considered potentially avoidable, tied to modifiable risk factors like tobacco use, excess weight, and alcohol consumption, which makes lung cancer’s continued death toll even harder to separate from decades of smoking history still working through the population.
Breast cancer illustrates the same pattern from a different angle. Roughly 382,640 new cases are expected in 2026, yet only 42,140 deaths, a ratio that reflects how effectively localized and regional breast cancer are now treated. The picture looks very different for the estimated 168,000 women currently living with stage 4 metastatic breast cancer, a population that is growing not because outcomes are worsening but because women are living meaningfully longer with the disease than they did a decade ago.
Access, Insurance, and Disparities in Stage 4 Diagnosis
Where a stage 4 diagnosis happens most often isn’t just a matter of biology. Insurance status, housing stability, and access to regular screening all shape whether a cancer is caught early or only after it has already spread.
Distant-Stage Diagnosis Rate, With vs. Without Federal Housing Assistance
| Cancer Type | With Housing Assistance | Without Housing Assistance |
|---|---|---|
| Breast | 6.7% | 7.2% |
| Colorectal | 22.2% | 23.3% |
| Lung, non-small cell | 51.4% | 54.2% |
Source: JAMA Network Open, propensity-matched cohort study of older US adults, 2026
The gap looks small in isolated percentage points, but across a population the size of Medicare enrollees, it translates into thousands of additional stage 4 diagnoses tied to housing insecurity alone. Researchers behind the study point to a plausible chain of cause and effect: stable housing tends to come with a fixed address for mail and appointment reminders, more consistent access to a primary care doctor, and fewer competing financial emergencies that push routine screening down the priority list.
Racial disparities in stage 4 outcomes remain just as persistent. Native American patients have the highest cancer mortality rate of any group tracked by national registries, with death rates roughly double those of White patients for cancers of the kidney, liver, stomach, and cervix. Non-Hispanic Black men also continue to face higher prostate cancer death rates than any other group, a gap that shows up even after accounting for stage at diagnosis, pointing to disparities in treatment access and follow-up care that persist well beyond the initial scan that confirms stage 4 disease.
Progress Since the 1990s: The Cancers That Improved Most
For the first time, more than 70% of Americans diagnosed with cancer between 2015 and 2021 are expected to survive at least five years, up from 63% in the mid-1990s. The improvement at distant stage specifically has been even sharper in relative terms.
5-Year Survival Rate, Distant Stage: Mid-1990s vs. 2026
| Cancer Type | Mid-1990s | 2015–2021 (Current) |
|---|---|---|
| All cancers combined | 17% | 35% |
| Myeloma | 32% | 62% |
| Liver | 7% | 22% |
| Melanoma | 16% | 35% |
| Rectal | 8% | 18% |
| Lung, regional stage | 20% | 37% |
| Lung, distant stage | 2% | 10% |
| Stomach | 3% | 8% |
Source: CA: A Cancer Journal for Clinicians, Cancer Statistics 2026
Distant-stage lung cancer’s move from a 2% to a 10% five-year survival rate looks small in absolute terms, but it represents a five-fold improvement, and it is arguably the single biggest treatment story in modern oncology. Immune checkpoint inhibitors like pembrolizumab, along with a wave of targeted therapies for patients whose tumors carry specific genetic mutations, turned a diagnosis that was once close to a uniform death sentence into one where a meaningful subset of patients now live five, sometimes ten, years past diagnosis. Cellular immunotherapies have made similar inroads for blood cancers; our <a href=”https://www.theglobalstatistics.com/car-t-cell-treatment-statistics-in-us/”>CAR T-cell treatment statistics report</a> covers how this newer approach is performing and what it costs patients.
Colorectal cancer’s distant-stage improvement, from 8% to 18% for rectal cancer specifically, has followed a similar path through a combination of better systemic chemotherapy, expanded use of targeted biologics, and more aggressive surgical approaches to isolated liver and lung metastases that were once considered untreatable. Myeloma’s jump from 32% to 62% stands out for a different reason: it reflects an entire new drug class, proteasome inhibitors and CAR-T cell therapy among them, reaching routine clinical use within a single generation of patients, something that took most other blood cancers considerably longer to achieve.
Colorectal Cancer at Stage 4: Why Younger Adults Are Changing the Picture
Colorectal cancer deserves its own closer look at stage 4, because the disease is currently moving in two directions at once: advanced-stage survival is improving, while the age at which people are first diagnosed keeps dropping.
Early-Onset Colorectal Cancer Trends, US
| Measure | Figure |
|---|---|
| New CRC cases in adults under 50 (2022) | 20,422 (13.8% of all CRC cases) |
| Share of CRC cases in adults 65 and under | 45% (up from 27% in 1995) |
| Annual incidence increase, ages 20–49 | 3% per year (2013–2022) |
| Share of under-50 cases diagnosed at advanced stage | 75% |
Source: American Cancer Society, Colorectal Cancer Statistics 2026; CA: A Cancer Journal for Clinicians
The 75% figure is the one oncologists point to most often when explaining why early-onset colorectal cancer has become such an urgent research priority. Adults under 50 aren’t just getting colorectal cancer more often; they’re also far less likely to be caught early, largely because routine screening still typically starts at 45 and younger patients and their doctors are less likely to attribute symptoms like rectal bleeding or persistent abdominal pain to colorectal cancer in the first place.
That diagnostic delay matters more for colorectal cancer than for almost any other common cancer type, given how sharply the survival curve drops between localized and distant stage. A rise in advanced-stage diagnoses among younger patients could offset some of the population-level survival gains described above, even as treatment for stage 4 disease continues to improve. Screening remains the single biggest lever available for catching this cancer before it reaches stage 4; our <a href=”https://www.theglobalstatistics.com/colonoscopy-screening-statistics-in-us/”>colonoscopy screening statistics report</a> breaks down current uptake rates and where the biggest screening gaps remain.
Clinical Trial Access for Stage 4 Patients
Experimental treatment access is frequently framed as an option available to any stage 4 patient willing to look for it, but the actual enrollment numbers tell a more limited story.
Cancer Clinical Trial Enrollment Rate by Care Setting, US
| Care Setting | Treatment Trial Enrollment Rate |
|---|---|
| NCI-designated comprehensive cancer center | 21.6% |
| Academic (non-NCI-designated) program | 5.4% |
| Integrated network cancer program | 5.7% |
| Community oncology program | 4.1% |
| National average, all settings | 7.1% |
Source: Journal of Clinical Oncology, Commission on Cancer accreditation data, 2013–2017
The five-fold gap between NCI-designated cancer centers and community programs matters enormously for stage 4 patients specifically, because more than 85% of American cancer care happens in community settings rather than academic centers. Geography compounds the problem further: roughly half of patients with common metastatic cancers would need to drive more than an hour one-way to reach a site running a relevant trial, a burden that falls hardest on rural patients and those without reliable transportation or paid time off work for frequent visits.
Newer genomic profiling technology has started to narrow this gap modestly. When patients with advanced non-small cell lung, colorectal, breast, or prostate cancer received comprehensive genomic profiling results, trial enrollment in their next line of therapy rose by about 3 percentage points, a meaningful jump given how low the baseline sits. Still, structural and logistical barriers, not patient reluctance, account for more than three in four cases where a stage 4 patient does not end up enrolling in a trial, according to national research on the topic.
The Financial Burden of Stage 4 Cancer Care
Advanced cancer treatment is not just a medical challenge; it is consistently the most expensive phase of cancer care by a wide margin, and the gap between early and late-stage costs has continued to widen.
Average Annual Cancer Care Cost by Phase, Older Adults, US
| Phase of Care | Average Annual Cost |
|---|---|
| First year after diagnosis | ~$45,100 |
| Continuing/maintenance care | ~$7,100 |
| Last year of life | ~$121,700 |
Source: JNCI: Journal of the National Cancer Institute, American Cancer Society/NCI joint study, July 2026
The nearly seventeen-fold jump between continuing care and end-of-life spending reflects the reality of advanced disease: more hospitalizations, more emergency department visits, more expensive oral cancer drugs, and often multiple simultaneous treatment lines as one approach after another is tried. Patients diagnosed with stage 4 pancreatic cancer who initiate chemotherapy in their final month of life see out-of-pocket costs rise more than 50% compared with those who don’t, while also spending fewer days in hospice care, a trade-off that researchers increasingly flag as a quality-of-life concern rather than a purely financial one.
These figures also help explain a pattern that shows up again and again in financial toxicity research: cancer patients are more likely to file for bankruptcy two or more years after diagnosis than in the immediate aftermath, once savings are depleted and the compounding costs of ongoing advanced-stage treatment catch up with household finances. Anyone researching the broader scope of this problem across the health system, not just oncology, can find additional context in our <a href=”https://www.theglobalstatistics.com/medical-debt-statistics-and-forgiveness-trends-in-us/”>medical debt statistics and forgiveness trends report</a>.
Stage 4 Cancer and End-of-Life Care Patterns
How stage 4 patients spend their final months has become its own area of active research, particularly around the tension between continuing aggressive treatment and shifting toward comfort-focused hospice care.
Stage 4 Pancreatic Cancer: Last 30 Days of Life, by Chemotherapy Status
| Measure | Continued Chemotherapy | No Late Chemotherapy |
|---|---|---|
| Average days in hospice care | 11.5 days | 15.7 days |
| Average out-of-pocket cost | $1,311.50 | $841.00 |
Source: PMC/National Cancer Institute-funded cohort study, Medicare beneficiaries aged 66+
The data shows a consistent trade-off: patients who continue chemotherapy into their final month of life spend roughly four fewer days in hospice care on average and pay over 50% more out of pocket during that period, without evidence that continued treatment meaningfully extends survival for most of this population. This has pushed several major cancer centers to revisit how and when end-of-life conversations happen with stage 4 patients, aiming to start them earlier rather than defaulting to continued treatment by momentum alone.
None of this is to suggest continued treatment is the wrong choice for every patient; some genuinely benefit, particularly those with targetable mutations or strong responses to immunotherapy. But the pattern does highlight how differently stage 4 cancer care can unfold depending on the conversations that happen between oncologists, patients, and families in the weeks after a terminal diagnosis is confirmed, and how much those conversations shape both quality of life and financial outcomes in ways that survival statistics alone don’t capture.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
